Home / Deep Research / Autosomal Recessive Dopa-Responsive Dystonia

Autosomal Recessive Dopa-Responsive Dystonia

Autosomal Recessive Dopa-Responsive Dystonia Deep Research Fallback

⚠️ Fallback MONDO:0011551

Autosomal Recessive Dopa-Responsive Dystonia Deep Research Fallback

Provider Attempts

  • just research-disorder falcon Autosomal_Recessive_Dopa_Responsive_Dystonia started and wrote only the startup line before remaining silent during the bounded wait; the process was terminated with signal 15 and produced no usable research artifact.
  • timeout 45s just research-disorder openai Autosomal_Recessive_Dopa_Responsive_Dystonia wrote only the startup line and was terminated by the timeout with signal 15; it produced no usable research artifact.

Literature Scope Used

Because both providers failed, the curation used structured Orphanet evidence plus manually selected PubMed references focused on tyrosine hydroxylase deficiency, dopa-responsive dystonia treatment, and the TSPOAP1/RIMBP1 recessive dystonia mechanism.

Key cached sources:

  • ORPHA:101150 for disease definition, inheritance, European prevalence, TH/TSPOAP1 gene rows, MONDO/OMIM/xref rows, and Orphanet phenotype-frequency rows.
  • PMID:20301610 for GeneReviews statements on TH-deficiency clinical spectrum, biallelic TH molecular diagnosis, autosomal recessive inheritance, and levodopa treatment response.
  • PMID:34834538 for expert-review support that DRD reflects defective dopamine synthesis and that TH catalyzes the rate-limiting step in catecholamine biosynthesis.
  • PMID:9703425 for human mutation evidence linking TH variants to autosomal recessive L-DOPA-responsive dystonia.
  • PMID:34054692 for a genetically diagnosed DRD cohort including TH variants and long-term levodopa outcomes.
  • PMID:30383639 for a human AR DRD case report with TH compound heterozygosity, clinical features, molecular diagnosis, and low-dose levodopa response.
  • PMID:33539324 for TSPOAP1 biallelic variants, human recessive dystonia, mouse RIMBP1-loss motor findings, and in vitro synaptic release evidence.

Curation Conclusions

  • The core TH disease mechanism is biallelic TH pathogenic variation causing decreased tyrosine hydroxylase activity, decreased catecholamine biosynthesis, and impaired central dopamine synthesis.
  • The phenotype spectrum is explicitly broad: mild TH-deficient dopa-responsive dystonia, infantile parkinsonism with motor delay, and progressive infantile encephalopathy.
  • All Orphanet frequent phenotype rows in ORPHA:101150 were represented with exact structured-cache snippets; occasional and very rare Orphanet rows that capture the severe spectrum were also included.
  • Molecular genetic testing, CSF neurotransmitter-metabolite findings, and levodopa responsiveness are the main diagnostic anchors available from the cached evidence.
  • Levodopa with a decarboxylase inhibitor is the evidence-backed treatment anchor; the YAML binds the action to MAXO:0000058 pharmacotherapy and the therapeutic agent to CHEBI:15765 L-dopa.
  • TSPOAP1 was included because ORPHA:101150 lists it as a disease-causing loss-of-function gene and PMID:33539324 provides human, mouse, and in vitro support for an autosomal recessive dystonia mechanism through presynaptic active-zone dysfunction.